Evidence map›Paper›PMID 34282198›Full record

SynthesisScientific reports2021

Meta-regression of randomized control trials with antithrombotics: weak correlation between net clinical benefit and all cause-mortality.

Roubi Kilo, Silvy Laporte, Rama Arab, Sabine Mainbourg, Steeve Provencher, Guillaume Grenet, Laurent Bertoletti, Laurent Villeneuve, Michel Cucherat, Jean-Christophe Lega and 1 more

Abstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Roubi KiloHospices Civils de Lyon, Hôpital Lyon Sud, Service de Recherche Et D'Epidémiologie Cliniques, Lyon, France. rubiskilo@hotmail.com.
Silvy LaporteUnité De Recherche Clinique, Innovation, Pharmacologie, Hôpital Nord, CHU De Saint-Étienne, Saint-Etienne, France.
Rama ArabUniv Lyon, Université Claude Bernard Lyon 1 - UMR CNRS 5558, Laboratoire de Biométrie Evolutive, Equipe Evaluation Et Modélisation Des Effets Thérapeutiques, Lyon, France.
Sabine MainbourgService De Médecine Interne Et Vasculaire, Hospices Civils De Lyon, Hôpital Lyon Sud, Lyon, France.
Steeve ProvencherPneumologue, Centre De Recherche De L'institut Universitaire De Cardiologie Et De Pneumologie De Québec, Québec, Canada.
Guillaume GrenetService Hospitalo Universitaire de PharmacoToxicologie, Pôle de Santé Publique, Hopsices Civils De Lyon, Lyon, France.
Laurent BertolettiService De Médecine Vasculaire Et Thérapeutique, Chu de Saint-Étienne, France.
Laurent VilleneuveHospices Civils de Lyon, Hôpital Lyon Sud, Service de Recherche Et D'Epidémiologie Cliniques, 69495, Pierre-Bénite, France.
Michel CucheratUniv Lyon, Université Claude Bernard Lyon 1 - UMR CNRS 5558, Laboratoire de Biométrie Evolutive, Equipe Evaluation Et Modélisation Des Effets Thérapeutiques, Lyon, France.
Jean-Christophe LegaService De Médecine Interne Et Vasculaire, Hospices Civils De Lyon, Hôpital Lyon Sud, Lyon, France.
META-EMBOL Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to explore the validity of the use of the net clinical benefit (NCB), i.e. the sum of major bleeding and thrombotic events, as a potential surrogate for all-cause mortality in clinical trials assessing antithrombotics. Published randomized controlled trials testing anticoagulants in the prevention or treatment of venous thromboembolism (VTE) and non-valvular atrial fibrillation (NVAF) were systematically reviewed. The validity of NCB as a surrogate endpoint was estimated by calculating the strength of correlation of determination (R

Indexed as

Atrial FibrillationCause of DeathDrug-Related Side Effects and Adverse ReactionsFibrinolytic AgentsHemorrhageHumansRandomized Controlled Trials as TopicRegression AnalysisRisk AssessmentStrokeSurvival AnalysisTreatment OutcomeVenous ThromboembolismFibrinolytic Agents

Identifiers

PMID34282198
PMCPMC8290002

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.